Open Access

Schisandrin A suppresses lipopolysaccharide-induced inflammation and oxidative stress in RAW 264.7 macrophages by suppressing the NF-κB, MAPKs and PI3K/Akt pathways and activating Nrf2/HO-1 signaling

  • Authors:
    • Da Hye Kwon
    • Hee-Jae Cha
    • Eun Ok Choi
    • Sun-Hee Leem
    • Gi-Young Kim
    • Sung-Kwon Moon
    • Young-Chae Chang
    • Seok-Joong Yun
    • Hye Jin Hwang
    • Byung Woo Kim
    • Wun-Jae Kim
    • Yung Hyun Choi
  • View Affiliations

  • Published online on: October 25, 2017     https://doi.org/10.3892/ijmm.2017.3209
  • Pages:264-274
  • Copyright: © Kwon et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

Schisandrin A is a bioactive lignan occurring in the fruits of plants of the Schisandra genus that have traditionally been used in Korea for treating various inflammatory diseases. Although the anti-inflammatory and antioxidant effects of lignan analogues similar to schisandrin A have been reported, the underlying molecular mechanisms have remained elusive. In the present study, schisandrin A significantly suppressed the lipopolysaccharide (LPS)-induced production of the key pro-inflammatory mediators nitric oxide (NO) and prostaglandin E2 by suppressing the expression of inducible NO synthase and cyclooxygenase-2 at the mRNA and protein levels in RAW 264.7 macrophages. Furthermore, schisandrin A was demonstrated to reduce the LPS-induced secretion of pro-inflammatory cytokines, including tumor necrosis factor-α and interleukin-1β; this was accompanied by a simultaneous decrease in the respective mRNA and protein levels in the macrophages. In addition, the LPS- induced translocation of nuclear factor-κB (NF-κB), as well as activation of mitogen-activated protein kinases (MAPKs) and phosphatidylinositol‑3 kinase (PI3K)/Akt pathways were inhibited by schisandrin A. Furthermore, schisandrin A significantly diminished the LPS-stimulated accumulation of intracellular reactive oxygen species, and effectively enhanced the expression of NF erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1). These results suggested that schisandrin A has a protective effect against LPS-induced inflammatory and oxidative responses in RAW 264.7 cells by inhibiting the NF-κB, MAPK and PI3K/Akt pathways; these effects are mediated, at least in part, by the activation of the Nrf2/HO-1 pathway. Based on these results, it is concluded that schisandrin A may have therapeutic potential for treating inflammatory and oxidative disorders caused by over-activation of macrophages.

Related Articles

Journal Cover

January 2018
Volume 41 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

2016 Impact Factor: 2.341
Ranked #21/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kwon, D.H., Cha, H., Choi, E.O., Leem, S., Kim, G., Moon, S. ... Choi, Y.H. (2018). Schisandrin A suppresses lipopolysaccharide-induced inflammation and oxidative stress in RAW 264.7 macrophages by suppressing the NF-κB, MAPKs and PI3K/Akt pathways and activating Nrf2/HO-1 signaling. International Journal of Molecular Medicine, 41, 264-274. https://doi.org/10.3892/ijmm.2017.3209
MLA
Kwon, D. H., Cha, H., Choi, E. O., Leem, S., Kim, G., Moon, S., Chang, Y., Yun, S., Hwang, H. J., Kim, B. W., Kim, W., Choi, Y. H."Schisandrin A suppresses lipopolysaccharide-induced inflammation and oxidative stress in RAW 264.7 macrophages by suppressing the NF-κB, MAPKs and PI3K/Akt pathways and activating Nrf2/HO-1 signaling". International Journal of Molecular Medicine 41.1 (2018): 264-274.
Chicago
Kwon, D. H., Cha, H., Choi, E. O., Leem, S., Kim, G., Moon, S., Chang, Y., Yun, S., Hwang, H. J., Kim, B. W., Kim, W., Choi, Y. H."Schisandrin A suppresses lipopolysaccharide-induced inflammation and oxidative stress in RAW 264.7 macrophages by suppressing the NF-κB, MAPKs and PI3K/Akt pathways and activating Nrf2/HO-1 signaling". International Journal of Molecular Medicine 41, no. 1 (2018): 264-274. https://doi.org/10.3892/ijmm.2017.3209